Share on LinkedInShare on LinkedIn

ARTICLE · 18 NOVEMBER 2026

Patenting Polymorphs In Europe: Key Considerations At The EPO

Pharmaceutical companies frequently use polymorph patents to extend patent protection beyond base compound patents, but obtaining such patents at the European Patent Office presents significant challenges. While novel crystalline forms can constitute patentable subject matter, establishing inventive step requires demonstrating unexpected technical advantages over known forms, and the EPO's case law in this area has produced nuanced and sometimes conflicting guidance that applicants must carefully navigate.

European UnionIntellectual Property

Polymorphs are different crystalline forms of the same chemical compound. In the pharmaceutical sector, different polymorphs can exhibit different properties, such as stability, hygroscopicity, dissolution behaviour, bioavailability and processability. As a result, polymorph patents are frequently used as part of pharmaceutical lifecycle management strategies, in order to extend patent protection for a pharmaceutical compound beyond the term of the base patent.

Although the European Patent Office (EPO) recognises that a novel crystalline form of a known compound can constitute patentable subject matter, Applicants can face challenges in establishing inventive step. Over the last fifteen years, the Boards of Appeal have developed a body of case law defining the circumstances in which polymorph inventions are, and are not, likely to be considered patentable. Unfortunately, the situation is not always clear and apparently conflicting judgments are often issued.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from